Drug Patents owned by Fresenius Kabi Usa

1. List of Acetaminophen drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741959 FRESENIUS KABI USA Paracetamol for parenteral administration
Apr, 2030

(7 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 28 October, 2015

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ACETAMINOPHEN family patents

4

European Union

3

United States

2

Spain

2

Poland

2

Denmark

1

Hong Kong

1

Hungary

1

Brazil

1

Australia

1

Portugal

1

China

1

Japan

2. List of Bortezomib drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962572 FRESENIUS KABI USA Bortezomib formulations
Nov, 2032

(9 years from now)

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 06 November, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

BORTEZOMIB family patents

3

United States

1

Canada

1

Australia

1

European Union

3. List of Caspofungin Acetate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636407 FRESENIUS KABI USA Caspofungin acetate formulations
Dec, 2032

(9 years from now)

Drugs and Companies using CASPOFUNGIN ACETATE ingredient

Market Authorisation Date: 30 December, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

CASPOFUNGIN ACETATE family patents

6

United States

1

Slovenia

1

Hong Kong

1

Hungary

1

Denmark

1

Spain

1

San Marino

1

Canada

1

Poland

1

Portugal

1

Cyprus

1

Lithuania

1

Croatia

1

European Union

4. List of Dilaudid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731082 FRESENIUS KABI USA Drug container
Apr, 2032

(9 years from now)

US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(11 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 January, 1984

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DILAUDID before it's patent expiration?
More Information on Dosage

DILAUDID family patents

10

United States

4

European Union

2

Australia

2

Spain

2

Portugal

2

Denmark

2

China

2

Japan

1

Hong Kong

1

IB

1

Hungary

1

Brazil

1

Canada

5. List of Diprivan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476010 FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Dec, 2024

(1 year, 9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476010

(Pediatric)

FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Jun, 2025

(2 years from now)

Drugs and Companies using PROPOFOL ingredient

Market Authorisation Date: 02 October, 1989

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DIPRIVAN before it's patent expiration?
More Information on Dosage

6. List of Fulvestrant drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833459 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(11 years from now)

US10188663 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(11 years from now)

US9271990 FRESENIUS KABI USA Fulvestrant formulations
May, 2034

(11 years from now)

Drugs and Companies using FULVESTRANT ingredient

Market Authorisation Date: 20 May, 2019

Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women

Dosage: SOLUTION;INTRAMUSCULAR

More Information on Dosage

7. List of Levothyroxine Sodium drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168238 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(9 years from now)

US9168239 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(9 years from now)

US9006289 FRESENIUS KABI USA Levothyroxine formulations
Oct, 2032

(9 years from now)

US11135190 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(13 years from now)

US9782376 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(13 years from now)

US10398669 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(13 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 24 June, 2011

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of LEVOTHYROXINE SODIUM before it's patent expiration?
More Information on Dosage

LEVOTHYROXINE SODIUM family patents

12

United States

1

Canada

1

European Union

8. List of Morphine Sulfate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072781 FRESENIUS KABI USA Morphine formulations
Mar, 2034

(11 years from now)

US9192608 FRESENIUS KABI USA Morphine formulations
Mar, 2034

(11 years from now)

US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(11 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Market Authorisation Date: 30 October, 2013

Treatment: Management of chronic pain in patients requiring opioid analgesia; Treatment of pain

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS

More Information on Dosage

MORPHINE SULFATE family patents

12

United States

6

European Union

4

China

3

Australia

2

Brazil

2

Canada

2

Japan

1

Hong Kong

1

Denmark

1

Spain

1

Portugal

9. List of Naropin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8118802 FRESENIUS KABI USA Connector for packaging containing medical fluids and packaging for medical fluids
May, 2023

(3 months from now)

US8162915 FRESENIUS KABI USA Connector for packings containing medical liquids, and corresponding packing for medical liquids
May, 2024

(1 year, 3 months from now)

US7828787 FRESENIUS KABI USA Connector for packaging containing medical fluids and packaging for medical fluids
Oct, 2025

(2 years from now)

US7857802 FRESENIUS KABI USA Connector for medical liquid-containing packages and medical liquid-containing packages
Nov, 2026

(3 years from now)

Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 September, 1996

Treatment: NA

Dosage: SOLUTION;INJECTION

How can I launch a generic of NAROPIN before it's patent expiration?
More Information on Dosage

NAROPIN family patents

9

European Union

5

Germany

4

United States

3

Hong Kong

3

Korea, Republic of

3

Brazil

3

Australia

3

Poland

3

Spain

3

Mexico

3

Japan

3

Slovenia

3

South Africa

3

Portugal

3

China

3

Norway

3

Canada

3

Denmark

2

Austria

1

India

10. List of Omegaven drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350186 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Nov, 2024

(1 year, 8 months from now)

US9629821 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(2 years from now)

US9566260 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 27, 2023
Orphan Drug Exclusivity (ODE) Jul 27, 2025

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 27 July, 2018

Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12; Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease; Treatment of liver disease through nutrition for patients under the age of 12

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage

OMEGAVEN family patents

6

United States

2

Australia

1

Canada

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in